ATProto Browser

Record data

{
  "uri": "at://did:plc:jyns4iqaejb7xz77cw7biox3/app.bsky.feed.post/3lidhtnemjc2h",
  "cid": "bafyreig7fapqs5lzzm7kje6ie5tf53ml7p7chswbaojmudtudei3qdzumm",
  "value": {
    "text": "Researchers at the National University of Singapore published a personalized cancer treatment strategy using red blood cell-derived vesicles (RBCEVs) to deliver antisense oligonucleotides (ASOs). This targeted approach suppresses EGFR in mutated cancer cells, sparing normal cells. #PrecisionOncology",
    "$type": "app.bsky.feed.post",
    "embed": {
      "$type": "app.bsky.embed.external",
      "external": {
        "uri": "https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00392-X/fulltext",
        "thumb": {
          "$type": "blob",
          "ref": {
            "$link": "bafkreic54uyaokdtr4wxvhxnvix6mgrgt3phepjsvxqitexpvqhmcven4m"
          },
          "mimeType": "image/jpeg",
          "size": 699701
        },
        "title": "Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer",
        "description": "Overall, by harnessing the specificity and efficacy of ASOs, we present an effective\nand adaptable therapeutic platform for NSCLC treatment."
      }
    },
    "langs": [
      "en"
    ],
    "facets": [
      {
        "index": {
          "byteEnd": 300,
          "byteStart": 282
        },
        "features": [
          {
            "tag": "PrecisionOncology",
            "$type": "app.bsky.richtext.facet#tag"
          }
        ]
      }
    ],
    "createdAt": "2025-02-17T00:17:30.562Z"
  }
}